Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend

Ocumension Therapeutics ( (HK:1477) ) just unveiled an update.

Ocumension Therapeutics has scheduled a board meeting for March 26, 2026, to review and approve the audited annual results for the year ended December 31, 2025. The board will also consider publishing these results and evaluating whether to recommend a final dividend to shareholders.

The planned meeting signals an upcoming disclosure of the company’s financial performance, which will be closely watched by investors for clues on its operational progress in the ophthalmic therapeutics market. Any decision on a final dividend could influence shareholder returns and may indicate management’s confidence in cash flow and future business prospects.

The most recent analyst rating on (HK:1477) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

More about Ocumension Therapeutics

Ocumension Therapeutics is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong, focusing on the development and commercialization of ophthalmic therapies. The company operates through various subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors with medical and industry expertise.

Its primary business is centered on treatments for eye diseases, positioning it within the specialized ophthalmology segment of the healthcare and pharmaceutical industry. By targeting vision-related conditions, Ocumension aims at the growing market for innovative eye-care solutions in Greater China and potentially broader international markets.

Average Trading Volume: 1,062,568

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.5B

Learn more about 1477 stock on TipRanks’ Stock Analysis page.